InvestorsHub Logo

Join the InvestorsHub Community

Register for free to join our community of investors and share your ideas. You will also get access to streaming quotes, interactive charts, trades, portfolio, live options flow and more tools.

Live Updating
profile icon
SuperC Free
12/28/10 12:23 PM
profile icon
carnelsonG Free
12/28/10 11:30 AM
profile icon
SuperC Free
12/28/10 11:19 AM
profile icon
carnelsonG Free
12/26/10 7:03 PM
profile icon
SuperC Free
12/25/10 3:35 PM
profile icon
mikembte2005 Free
12/23/10 5:34 PM
profile icon
carnelsonG Free
12/23/10 4:02 PM
profile icon
carnelsonG Free
12/23/10 8:27 AM
profile icon
mikembte2005 Free
11/09/10 9:51 PM
profile icon
mikembte2005 Free
11/03/10 10:58 PM
profile icon
mikembte2005 Free
09/19/10 2:55 PM
profile icon
mikembte2005 Free
09/15/10 7:37 PM
profile icon
carnelsonG Free
09/15/10 9:30 AM
profile icon
mikembte2005 Free
09/14/10 9:14 PM
profile icon
mikembte2005 Free
08/16/10 7:26 PM
profile icon
carnelsonG Free
08/07/10 12:31 PM
profile icon
mikembte2005 Free
08/07/10 11:42 AM
profile icon
mikembte2005 Free
07/20/10 11:45 PM
profile icon
carnelsonG Free
06/07/10 3:08 PM
profile icon
mikembte2005 Free
05/07/10 10:02 AM
profile icon
carnelsonG Free
05/05/10 12:47 AM
profile icon
mikembte2005 Free
05/04/10 8:28 PM
profile icon
mikembte2005 Free
04/01/10 10:14 PM
profile icon
mikembte2005 Free
04/01/10 9:56 PM
profile icon
mikembte2005 Free
04/01/10 9:53 PM
profile icon
mikembte2005 Free
04/01/10 9:52 PM
profile icon
mikembte2005 Free
04/01/10 8:00 PM
profile icon
mikembte2005 Free
04/01/10 7:58 PM
profile icon
mikembte2005 Free
04/01/10 7:54 PM
profile icon
mikembte2005 Free
04/01/10 7:52 PM
profile icon
mikembte2005 Free
04/01/10 4:16 PM
profile icon
mikembte2005 Free
04/01/10 4:14 PM
profile icon
mikembte2005 Free
04/01/10 2:55 PM
profile icon
carnelsonG Free
04/01/10 1:47 PM
profile icon
mikembte2005 Free
04/01/10 1:46 PM
profile icon
mikembte2005 Free
03/26/10 11:04 AM
profile icon
mikembte2005 Free
03/26/10 9:59 AM
profile icon
mikembte2005 Free
03/25/10 7:05 PM
profile icon
mikembte2005 Free
03/19/10 7:08 AM

RxElite, Inc. (RXEI) RSS Feed

Followers
10
Posters
12
Posts (Today)
0
Posts (Total)
220
Created
10/21/08
Type
Free
Moderators

About RxElite, Inc. dba Landela Pharmaceutical

RxElite, Inc. dba Landela Pharmaceutical is a specialty pharmaceutical company that develops and markets generic prescription drug products in specialty generic markets. The Company also operates an Israeli subsidiary that manufactures and markets complex active pharmaceutical ingredients and provides research and development services to pharmaceutical companies throughout the world.

http://www.landelapharma.com/releases/57-rxelite-inc-shareholder-update

SUBSIDIARY:    FINETECH PHARMACEUTICAL 

http://www.finetechlabs.com/index.php?option=com_content&task=view&id=20&Itemid=29

RxElite, Inc. Shareholder Update PDF Print E-mail
Thursday, 12 February 2009 09:50

Meridian, Idaho, February 12, 2009:  RxElite, Inc. [RXEI.PK] announced today that it has determined to suspend reporting currently with the SEC.  On February 3, 2009, RxElite filed Form 15, Certificate and Notice of Termination of Registration under Section 12(g) of the Securities Exchange Act of 1934, and no longer will be required to file mandatory reports with the SEC.  According to Earl Sullivan, Chairman and CEO, “We made this decision in consultation with our senior lenders after which our board authorized suspension of reporting as a measure designed to reduce overhead and compliance costs following our recent sale of RxElite Holdings Inc., our wholly owned U.S. subsidiary, to Piramal Healthcare Limited (India).”

On February 2, 2009, RxElite, Inc. also commenced activities as “Landela Pharmaceutical.” The name change will allow the Company to distinguish itself from its former subsidiary, RxElite Holdings Inc.  The Company fully intends to differentiate itself through products, marketing, and distribution channels to be solely known as Landela Pharmaceutical.

In recognition of the changes to the Company’s activity and operations, Peter Williams, David Rector and Mark Auerbach submitted their resignations as members of the board of directors.  Their resignations were not a result of any disagreement or dispute with the Company but reflect further efforts to streamline the corporate structure and assist the Company in reducing overhead and administrative burdens.  Mr. Sullivan stated “The Company would like to express its heartfelt thanks to its former directors for their untiring service during the difficult period in which we have successfully achieved a major milestone by selling our anesthetic gas business to a highly qualified buyer in a cash transaction.”

The Company remains committed to growing its remaining business as an active pharmaceutical manufacturer through its subsidiary FineTech Pharmaceutical, Ltd., based in Israel.  Furthermore, the new management team of Landela Pharmaceutical intends to continue to increase its pipeline of abbreviated new drug application (ANDA) filings.  The new management at Landela Pharmaceutical has made significant cost savings measures, including seeking relief from SEC reporting, reduced pay for all senior executives, reduction in staffing, and reduction in various overhead items.  In addition, the Company terminated the lease for the new corporate offices in Nampa, Idaho and has been released from all contingent obligations related to the lease.

Landela Pharmaceutical has filed two new ANDAs in the past 90 days and one Prior Approval Supplement (PAS) for a current ANDA.  The Company is in the process of reestablishing wholesaler contracts and updating all regulatory records to reflect the new structure.  The Company remains committed to finding additional development partners for additional ANDA filings and licensing opportunities for ANDAs.

The Company would like to remind its shareholders that it will announce by press release future times when conferences may be held to provide updates to shareholders.  To update your contact information, please contact Earl Sullivan, CEO at
earl.sullivan@landelapharma.com This e-mail address is being protected from spambots. You need JavaScript enabled to view it or Shannon Stith, VP of Finance at shannon.stith@landelapharma.com This e-mail address is being protected from spambots. You need JavaScript enabled to view it .  You may also request information by writing to Landela Pharmaceutical, 776 East Riverside Drive, Suite 150 Eagle, Idaho 83616.


per knobias

Authorized Shares: 200,000,000
Source: 8-K ( 10/29/2007 )

Outstanding Shares: 119,705,157
Source: MGFS ( 11/11/2008 ) 

 

Volume:
Day Range:
Last Trade Time:
  • 1D
  • 1M
  • 3M
  • 6M
  • 1Y
  • 5Y
RXEI Latest News
  • No Recent News Available for this company!
New Post